7,724 Shares of Danaher Corporation $DHR Purchased by Finward Bancorp

Key Points

• Finward Bancorp acquired 7,724 Danaher shares worth approximately $1.71 million in the third quarter, making Danaher 1.2% of its portfolio. Institutional investors collectively own 79.05% of Danaher.
• Danaher reported quarterly EPS of $1.94, beating estimates of $1.85, while revenue rose 5.5% year over year to $6.26 billion. The company also declared a quarterly dividend of $0.40 per share, equal to a 0.7% annualized yield.
• Analysts maintain a favorable view, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $235.41. Danaher’s collaboration with NVIDIA on AI-powered autonomous science offers a potential long-term growth catalyst.

Finward Bancorp purchased a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 7,724 shares of the conglomerate's stock, valued at approximately $1,711,000. Danaher comprises about 1.2% of Finward Bancorp's investment portfolio, making the stock its 23rd largest position.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Columbus Macro LLC bought a new position in Danaher in the 3rd quarter valued at $5,213,000. Virginia Wealth Management Group Inc. bought a new position in shares of Danaher in the third quarter worth about $12,484,000. Union Savings Bank raised its stake in shares of Danaher by 258.6% in the third quarter. Union Savings Bank now owns 7,883 shares of the conglomerate's stock worth $1,746,000 after acquiring an additional 5,685 shares during the last quarter. Elmwood Wealth Management Inc. raised its stake in shares of Danaher by 73.2% in the third quarter. Elmwood Wealth Management Inc. now owns 9,986 shares of the conglomerate's stock worth $2,212,000 after acquiring an additional 4,222 shares during the last quarter. Finally, Essex LLC acquired a new position in shares of Danaher during the third quarter worth approximately $4,692,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 0.8%

DHR opened at $224.65 on Thursday. The firm has a 50 day simple moving average of $212.92 and a 200 day simple moving average of $195.39. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a market cap of $157.93 billion, a price-to-earnings ratio of 39.90, a price-to-earnings-growth ratio of 2.80 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to analysts' expectations of $6.12 billion. During the same period last year, the firm earned $0.77 earnings per share. The business's revenue for the quarter was up 5.5% on a year-over-year basis. On average, sell-side analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio is 28.42%.

Analyst Ratings Changes

Several research firms have recently commented on DHR. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. Evercore restated an "outperform" rating and issued a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. TD Cowen boosted their price objective on shares of Danaher from $236.00 to $255.00 and gave the stock a "buy" rating in a research report on Tuesday. Guggenheim upped their price objective on Danaher from $200.00 to $250.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. Finally, Morgan Stanley increased their price objective on Danaher from $220.00 to $240.00 and gave the company an "overweight" rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $235.41.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.